VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice

ABSTRACT Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.

[1]  D. A. Stein,et al.  Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers , 2006, PLoS pathogens.

[2]  E. Mühlberger,et al.  The Ebola Virus Genomic Replication Promoter Is Bipartite and Follows the Rule of Six , 2005, Journal of Virology.

[3]  Peter Kuhn,et al.  Inhibition, Escape, and Attenuated Growth of Severe Acute Respiratory Syndrome Coronavirus Treated with Antisense Morpholino Oligomers , 2005, Journal of Virology.

[4]  D. A. Stein,et al.  Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity. , 2005, Bioconjugate chemistry.

[5]  D. A. Stein,et al.  Inhibition of Flavivirus Infections by Antisense Oligomers Specifically Suppressing Viral Translation and RNA Replication , 2005, Journal of Virology.

[6]  D. A. Stein,et al.  Inhibition of Dengue Virus Serotypes 1 to 4 in Vero Cell Cultures with Morpholino Oligomers , 2005, Journal of Virology.

[7]  T. Meyer,et al.  Inhibition of Marburg virus protein expression and viral release by RNA interference. , 2005, The Journal of general virology.

[8]  Sina Bavari,et al.  The evolving field of biodefence: therapeutic developments and diagnostics , 2005, Nature Reviews Drug Discovery.

[9]  I. Dokal,et al.  Dyskeratosis congenita: molecular insights into telomerase function, ageing and cancer , 2004, Expert Reviews in Molecular Medicine.

[10]  G. Neumann,et al.  Rescue of Ebola virus from cDNA using heterologous support proteins. , 2004, Virus research.

[11]  L. Hensley,et al.  Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions , 2004, Expert Reviews in Molecular Medicine.

[12]  M. Aman,et al.  Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. , 2004, Vaccine.

[13]  H. Young,et al.  Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection , 2004, The Journal of experimental medicine.

[14]  D. A. Stein,et al.  Antisense Morpholino-Oligomers Directed against the 5′ End of the Genome Inhibit Coronavirus Proliferation and Growth† , 2004, Journal of Virology.

[15]  P. Iversen,et al.  Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. , 2004, Bioconjugate chemistry.

[16]  P. Jahrling,et al.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys , 2003, The Lancet.

[17]  R. Ahmed,et al.  Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. , 2003, Virology.

[18]  H. Klenk,et al.  The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3 , 2003, Journal of Virology.

[19]  Ziying Han,et al.  Biochemical and Functional Characterization of the Ebola Virus VP24 Protein: Implications for a Role in Virus Assembly and Budding , 2003, Journal of Virology.

[20]  J. Heasman.  Morpholino oligos: making sense of antisense? , 2002, Developmental biology.

[21]  P. Jahrling,et al.  Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. , 2002, Immunology letters.

[22]  R. Silverman,et al.  Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. , 2002, Virology.

[23]  D. A. Stein,et al.  Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. , 2001, Antisense & nucleic acid drug development.

[24]  R. Ahmed,et al.  Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral Replication , 2001, Journal of Virology.

[25]  Shinji Watanabe,et al.  Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein , 2001, Journal of Virology.

[26]  V. Volchkov,et al.  The Ebola virus VP35 protein functions as a type I IFN antagonist. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Rosenblatt,et al.  Analysis of gene-specific DNA damage and repair using quantitative polymerase chain reaction. , 2000, Methods.

[28]  Stephan Becker,et al.  Comparison of the Transcription and Replication Strategies of Marburg Virus and Ebola Virus by Using Artificial Replication Systems , 1999, Journal of Virology.

[29]  P. Jahrling,et al.  Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. , 1999, The Journal of infectious diseases.

[30]  H. Klenk,et al.  Three of the Four Nucleocapsid Proteins of Marburg Virus, NP, VP35, and L, Are Sufficient To Mediate Replication and Transcription of Marburg Virus-Specific Monocistronic Minigenomes , 1998, Journal of Virology.

[31]  H. Klenk,et al.  Interactions of Marburg virus nucleocapsid proteins. , 1998, Virology.

[32]  M. Bray,et al.  A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. , 1998, The Journal of infectious diseases.

[33]  J. Summerton,et al.  Morpholino antisense oligomers: design, preparation, and properties. , 1997, Antisense & nucleic acid drug development.

[34]  R. A. Killington,et al.  Virus isolation and quantitation , 1996, Virology Methods Manual.

[35]  I. Borisevich,et al.  [The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever]. , 1994, Voprosy virusologii.

[36]  A. Sanchez,et al.  Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. , 1993, Virus research.

[37]  K. Johnson,et al.  MARBURG-VIRUS DISEASE IN KENYA , 1982, The Lancet.

[38]  J B Moe,et al.  Plaque Assay for Ebola Virus , 1981, Journal of clinical microbiology.

[39]  P. Iversen,et al.  Evaluation of antisense mechanisms of action. , 2000, Methods in enzymology.

[40]  J. McCormick,et al.  Experimental filovirus infections. , 1999, Current topics in microbiology and immunology.

[41]  C. Peters,et al.  Filovirus diseases. , 1999, Current topics in microbiology and immunology.

[42]  H. Feldmann,et al.  Classification, structure, and replication of filoviruses. , 1999, Current topics in microbiology and immunology.

[43]  P. Jahrling,et al.  Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. , 1996, Archives of virology. Supplementum.

[44]  D. Barofsky,et al.  Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. , 1996, Antisense & nucleic acid drug development.

[45]  B. Mahy,et al.  Virology methods manual , 1996 .